
Eledon Pharmaceuticals, Inc.
ELDNNasdaqCIK 1404281HealthcareFiscal year ends Dec 31
Reports and events: 212 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-08-1316:30 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-349314 |
| 2026-08-1316:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-349170 |
| 2026-06-2217:00 ET | 8-K | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-277653 |
| 2026-05-1316:20 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-221702 |
| 2026-05-1316:15 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-221658 |
| 2026-04-3016:57 ET | DEF 14A | Proxy statementPeriod 2026-06-18 | 0001193125-26-197732 |
| 2026-03-1917:05 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001193125-26-116164 |
| 2026-03-1917:02 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-116154 |
| 2026-01-0216:30 ET | 8-K | 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-26-000968 |
| 2025-11-1417:11 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-283294 |
| 2025-11-1417:05 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-283275 |
| 2025-11-1320:55 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-25-278392 |
| 2025-11-0718:44 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-270286 |
| 2025-08-1417:11 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001193125-25-180906 |
| 2025-08-1417:08 ET | 10-Q/A | Quarterly report, amendedPeriod 2025-03-31 | 0001193125-25-180904 |
| 2025-08-1416:46 ET | 10-K/A | Annual report, amendedPeriod 2024-12-31 | 0001193125-25-180865 |
| 2025-08-1416:30 ET | 8-K | 2.02 Results of operations; 4.02 Non-reliance on financial statements; 9.01 Financial statements and exhibits | 0001193125-25-180820 |
| 2025-08-0616:03 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-25-103975 |
| 2025-06-1217:28 ET | 8-K | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0000950170-25-085588 |
| 2025-05-1417:00 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0000950170-25-071582 |
| 2025-05-1416:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-071370 |
| 2025-04-2917:00 ET | DEF 14A | Proxy statementPeriod 2025-06-10 | 0000950170-25-060299 |
| 2025-04-1417:00 ET | 8-K/A | 4.01 Change of auditor; 9.01 Financial statements and exhibits | 0000950170-25-053765 |
| 2025-04-0717:00 ET | 8-K | 4.01 Change of auditor; 9.01 Financial statements and exhibits | 0000950170-25-051663 |
| 2025-03-2017:00 ET | 10-K | Annual reportPeriod 2024-12-31 | 0000950170-25-042754 |
| 2025-03-2016:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-042644 |
| 2024-12-2008:00 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0000950170-24-138782 |
| 2024-11-1217:00 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0000950170-24-125622 |
| 2024-11-1216:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-125340 |
| 2024-10-3021:27 ET | 8-K | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-118497 |
| 2024-10-2908:00 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-117946 |
| 2024-10-0116:30 ET | 8-K | 3.02 Unregistered sale of equity | 0000950170-24-110857 |
| 2024-09-2017:00 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0000950170-24-108465 |
| 2024-08-1916:36 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0000950170-24-098590 |
| 2024-08-1916:33 ET | 10-Q/A | Quarterly report, amendedPeriod 2024-03-31 | 0000950170-24-098582 |
| 2024-08-1916:30 ET | 10-K/A | Annual report, amendedPeriod 2023-12-31 | 0000950170-24-098575 |
| 2024-08-1417:15 ET | 8-K | 2.02 Results of operations; 4.02 Non-reliance on financial statements; 9.01 Financial statements and exhibits | 0000950170-24-097206 |
| 2024-07-1216:30 ET | 8-K | 4.01 Change of auditor; 9.01 Financial statements and exhibits | 0000950170-24-083220 |
| 2024-07-1016:47 ET | 8-K | 3.02 Unregistered sale of equity | 0000950170-24-082739 |
| 2024-07-1016:41 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-24-082730 |
| 2024-05-3016:05 ET | DEF 14A | Proxy statementPeriod 2024-07-10 | 0000950170-24-066564 |
| 2024-05-1507:00 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0000950170-24-060025 |
| 2024-05-1316:30 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-058706 |
| 2024-05-0707:15 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-053934 |
| 2024-04-2617:00 ET | 10-K/A | Annual report, amendedPeriod 2023-12-31 | 0000950170-24-049277 |
| 2024-03-2816:30 ET | 10-K | Annual reportPeriod 2023-12-31 | 0000950170-24-038091 |
| 2024-03-2816:01 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-038008 |
| 2023-11-0917:00 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0000950170-23-062203 |
| 2023-11-0916:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-062007 |
| 2023-11-0216:30 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-23-058279 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 30, 2026, 11:26 ET. Listed shows no prices and gives no investment advice.